Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by Bella2017on Apr 28, 2017 1:55am
159 Views
Post# 26177794

RE:RE:"Bringing REAL science to pharmaceutical cannabis"

RE:RE:"Bringing REAL science to pharmaceutical cannabis" Good article!



sunny3999 wrote:

Why CBD is the Key to Unlocking the Cannabis Industry's Potential

Ethan Andersen  | 

Those that have been closely following the journey of medical marijuana in the public spotlight will know that, while it was once looked at with distrust and skepticism, it's now widely regarded as a legitimate medical treatment that should be available whenever possible. The principle compound in cannabis responsible for wellness benefits, known as cannabidiol, is gaining traction in the U.S. pharmaceutical and medical industries as an effective, inexpensive, and non-psychoactive form of medical relief, and its scientifically-backed stance as such is aiding the medical cannabis industry to an enormous extent. 

Here's What Medical Cannabis Experts Have to Say About the Compound:

 

Prateek Dwivedi, CEO of Ehave (OTCQB: EHVVF)

"The potential for medical cannabis to remove its stigma grows drastically when strains with high CBD are proven to give healthier outcomes to their target diseases, while ensuring the side effect of the "high" from the THC is minimized. These strains will open the doors to greater clinician adoption and patient acceptance, and give medical cannabis the chance to be considered as sophisticated as pharmaceuticals. This can only happen when high quality clinical and research data is captured to prove the efficacy."

Robert Farrell, President of Kalytera Therapeutics (TSXV: KALY)

"Cannabidiol ('CBD') is one of the principal chemical compounds found in the marijuana and hemp plants. Unlike the other principal compound, THC, CBD is not psychoactive - it does not make you 'high.' CBD has been shown to have activity against a number of potential disease targets, and is currently be evaluated in human clinical studies. It is a remarkable compound, with great promise as a treatment for several diseases and disorders."


 

 

 


 

Nick Jack, General Manager at Diego Pellicer - Colorado

"CBD is just one of many different cannabinoids found in the marijuana plant. This cannabinoid is non-psychoactive which means it won't alter your state of mind, however the medicinal benefits from CBD range from anti-inflammation, to pain relief, and even cancer treatment. Whether you're an everyday user or someone who's never partaken, CBD is a healthy alternative medicine that's worth your research."

Ben Sheppard, CEO of Jane's Brew

"We can clearly see the proliferation and acceptance of CBD in the U.S., particularly hemp-derived CBD, and it will likely continue to proliferate over the next 36 months. The health benefits of CBD include pain relief, relaxation, and deeper sleep. Meanwhile, the use of CBD as a form of medical relief saves patients thousands of dollars a year, given its low cost in relation to prescription drugs, and can help successfully keep them off of opiates."

Danny Davis, Managing Partner at Convectium

"For many, the medicinal benefits of the cannabis plant without the non-psychotic effects of THC, otherwise known as CBD, is a daily must have to function. We think the ambiguity around its legality and use scenarios will start to be more well defined and thus expect a massive uptick in its demand and availability."

DISCLOSUREThe views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: https://www.equities.com/disclaimer




Bullboard Posts